Anonymous
Guest
Anonymous
Guest
First management is hell bent on namenda reports. Nothing was important as them -for a year. Then the hot shit button was the business plan. What a huge deal. Then it went away. Now the PDE report is holier than thou. What will be next, a Aricept generic report? Will sales people have to go into the biggest Aricept generic users and threaten that they are doing their patients wrong by not using 23mg?